A61P 3/04
Anorexiants
Official title: Anorexiants; Antiobesity agents
A61P3/04 (Anorexiants) appears on 14,197 US grants and 22,866 published applications in this corpus.
Search patents in A61P- Granted patents
- 14,197
- Published applications
- 22,866
- Assignees
- 5,025
- Inventors
- 32,092
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 3 | 0 |
| 1978 | 7 | 0 |
| 1979 | 1 | 0 |
| 1980 | 9 | 0 |
| 1981 | 11 | 0 |
| 1982 | 8 | 0 |
| 1983 | 3 | 0 |
| 1984 | 9 | 0 |
| 1985 | 5 | 0 |
| 1986 | 7 | 0 |
| 1987 | 14 | 0 |
| 1988 | 7 | 0 |
| 1989 | 15 | 0 |
| 1990 | 21 | 0 |
| 1991 | 25 | 0 |
| 1992 | 17 | 0 |
| 1993 | 19 | 0 |
| 1994 | 26 | 0 |
| 1995 | 30 | 0 |
| 1996 | 39 | 0 |
| 1997 | 42 | 0 |
| 1998 | 90 | 0 |
| 1999 | 77 | 0 |
| 2000 | 108 | 0 |
| 2001 | 168 | 62 |
| 2002 | 233 | 379 |
| 2003 | 255 | 618 |
| 2004 | 230 | 935 |
| 2005 | 265 | 987 |
| 2006 | 368 | 1069 |
| 2007 | 478 | 1194 |
| 2008 | 521 | 1326 |
| 2009 | 571 | 1548 |
| 2010 | 829 | 1865 |
| 2011 | 830 | 1476 |
| 2012 | 1005 | 1399 |
| 2013 | 1067 | 1142 |
| 2014 | 1056 | 1053 |
| 2015 | 917 | 1020 |
| 2016 | 723 | 955 |
| 2017 | 727 | 838 |
| 2018 | 644 | 728 |
| 2019 | 547 | 709 |
| 2020 | 477 | 660 |
| 2021 | 451 | 588 |
| 2022 | 287 | 495 |
| 2023 | 261 | 477 |
| 2024 | 258 | 496 |
| 2025 | 287 | 477 |
| 2026 | 148 | 370 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Use of ionic polymers in biomass processing for preparation of animal feed additive6 Oct 2026US 12,751,470 B2Embion Technologies SA
- Means for specifically eliminating perilipin-1 fragment presenting adipocytes29 Sep 2026US 12,747,286 B2Alytas Therapeutics GmbH
- GABA-containing composition22 Sep 2026US 12,740,956 B2Kyoto Prefectural Public University Corporation
- Composition for preventing, ameliorating, or treating metabolic syndromes including obesity, diabetes, hyperlipidemia, and fatty liver22 Sep 2026US 12,741,007 B2Nutracore Co., Ltd.
- GLP1R agonist NMDAR antagonist conjugates22 Sep 2026US 12,742,006 B2Københavns Universitet
- Lipolytic and antiadipogenic coumarin derivatives8 Oct 2026US 2026/0306446 A1Karl-Franzens-Universität Graz
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Alk7 combination treatments8 Oct 2026US 2026/0306628 A1
- Compositions and methods using thymol and/or carvacrol for induction of autophagy1 Oct 2026US 2026/0294840 A1Societe des Produits Nestle S. A.
- Methods for weight loss and/or reducing weight gain1 Oct 2026US 2026/0294867 A1The Medical College of Wisconsin, Inc.
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- Method and apparatus for intracellular electro-manipulation425US 6,326,177 B1Eastern Virginia Medical School of the Medical College of Hampton Roads · 2001
- Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties371US 6,271,278 B1Purdue Research Foundation · 2001